{"entity":{"id":"cd20","kind":"target","name":"CD20","aka":[],"tldr":"CD20 is a B-cell marker; rituximab against it was the first antibody approved for cancer, in 1997.","summary":"CD20 (MS4A1) is a B-cell tetraspanin that regulates calcium flux; it is not internalised, which favours effector-based antibodies and T-cell engagers over ADCs, and it is present on over 95% of DLBCL and, more dimly, over 90% of CLL. It is the target of rituximab, the first antibody approved for cancer in 1997, and of obinutuzumab. The CD20×CD3 bispecifics glofitamab, epcoritamab, mosunetuzumab, and odronextamab now offer off-the-shelf T-cell redirection in lymphoma without the manufacturing wait of CAR-T. Loss of CD20 expression is a recognised escape route after repeated anti-CD20 therapy, and the best sequencing of bispecifics versus CAR-T is still being worked out. The simple version is the B-cell marker that started antibody therapy for cancer and now anchors the newest T-cell engagers.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/CD20","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/CD20"}],"tags":["antibody-target"],"related":[],"indications":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["ibritumomab-tiuxetan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"MS4A1","hgnc":"HGNC:7315","ensembl":"ENSG00000156738","uniprot":"P11836","entrez":"931","biology":"CD20 is a tetraspanin regulating B-cell calcium flux; it is not internalised, favouring effector-based antibodies over ADCs.","whereFound":["DLBCL","Follicular lymphoma","CLL","Mantle cell lymphoma"],"targetClass":"surface-antigen","prevalence":[{"indicationId":"dlbcl","pct":">95","measure":"Surface expression","source":"https://en.wikipedia.org/wiki/CD20"}]},"route":"/targets/cd20/","neighbours":{"indication":[{"id":"dlbcl","kind":"indication","name":"Diffuse large B-cell lymphoma","route":"/indications/dlbcl/"},{"id":"follicular-lymphoma","kind":"indication","name":"Follicular lymphoma","route":"/indications/follicular-lymphoma/"}],"drug":[{"id":"ibritumomab-tiuxetan","kind":"drug","name":"Ibritumomab tiuxetan","route":"/drugs/ibritumomab-tiuxetan/"},{"id":"i-131-tositumomab","kind":"drug","name":"Iodine-131 tositumomab","route":"/drugs/i-131-tositumomab/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"}],"institution":[{"id":"sant-orsola-bologna","kind":"institution","name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola","route":"/institutions/sant-orsola-bologna/"}],"pairing":[{"id":"rituximab-then-ibritumomab-tiuxetan","kind":"pairing","name":"Rituximab pretreatment before ibritumomab tiuxetan (Zevalin)","route":"/pairings/rituximab-then-ibritumomab-tiuxetan/"}],"technology":[{"id":"pretargeted-radioimmunotherapy","kind":"technology","name":"Pretargeted radioimmunotherapy","route":"/technologies/pretargeted-radioimmunotherapy/"}]}}